Opioid switching from oral slow release morphine to oral methadone may improve pain control in chronic non-malignant pain: A nine-month follow-up study

Palliative Medicine

Volumn 20, Issue 1, 2006, Pages 35-41

  Fredheim, Olav Magnus S ^a   Kaasa, Stein ^a,b   Dale, Ola ^a,b   Klepstad, Pål ^a,b   Landrø, Nils Inge ^a,c   Borchgrevink, Peter C ^a,b  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

Chronic pain; Methadone; Neuropsychology; Opioid switch; Quality of life

Indexed keywords

FENTANYL; METHADONE; MORPHINE; NALOXONE; NARCOTIC ANALGESIC AGENT; OXYCODONE;

ADULT; AGED; ANXIETY DISORDER; ARTICLE; CHRONIC PAIN; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CONTROL; DROWSINESS; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG SUBSTITUTION; FEMALE; FOLLOW UP; HUMAN; LONG TERM CARE; MALE; OPEN STUDY; PATIENT ATTITUDE; PHYSICAL CAPACITY; PROSPECTIVE STUDY; QUALITY OF LIFE; SEDATION; SIDE EFFECT; SLOW RELEASE FORMULATION; SOMNOLENCE; SWEATING; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; ANALGESICS, OPIOID; CHRONIC DISEASE; DELAYED-ACTION PREPARATIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; METHADONE; MIDDLE AGED; MORPHINE; PAIN; PATIENT SATISFACTION; PROSPECTIVE STUDIES;

EID: 32444437868     PISSN: 02692163     EISSN: None     Source Type: Journal    
DOI: 10.1191/0269216306pm1099oa     Document Type: Article

References (25)

1. Eriksen J. Opioids in chronic non-malignant pain. Eur J Pain 2001; 5: 231-32.
2. Thomsen A, Becker N, Eriksen J. Opioid rotation in chronic non-malignant pain patients. Acta Anaesthesiol Scand 1999; 43: 918-23.
3. Mercadante S, Casuccio A, Fulfaro F, et al. Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study. J Clin Oncol 2001; 19: 2898-904.
4. Hanks GW, de Conno F, Cherny N, et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 2001; 84: 587-93.
5. Cherny N, Ripamonti C, Pereira J, et al. Strategies to manage the adverse effects of oral morphine. An evidence-based report. J Clin Oncol 2001; 19: 2542-54.
6. Hays H, Woodroffe MA. Use of methadone in treating chronic non-malignant pain. Pain Res Manage 1999; 4: 23-27.
7. Quang-Cantagrel N, Wallace MS, Magnuson SK. Opioid substitution to improve the effectiveness of chronic noncancer pain control: a chart review. Anesthesia Analg 2000; 90: 933-37.
8. Kalso E, Allan L, Dellemijn P, et al. Recommendations for using opioids in non-cancer pain. Eur J Pain 2003; 7: 381-86.
9. Aaronson NK, Ahmedzai S, Bergman B, et al for the European Organization for Research and Treatment of Cancer Study group on Quality of Life. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-76.
10. Lawlor P, Turner K, Hanson J, Bruera E. Dose ratio between morphine and methadone in patients with cancer pain. Cancer 1998; 82: 1167-73.
11. Gagnon B, Bruera E. Differences in the ratios of morphine to methadone in patients with neuropathic pain versus non-neuropathic pain. J Pain Symptom Manage 1999; 18: 120-25.
12. Ripamonti C, Groff L, Brunelli C, Polastri D, Stavrakis A, De Conno F. Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio? J Clin Oncol 1998; 16: 3216-21.
13. Keller S, Bann C, Dodd SL, Schein J, Mendoza T, Cleeland CS. Validity of the Brief Pain Inventory for use in documenting the outcomes of patients with noncancer pain. Clin J Pain 2004; 20: 309-18.
14. Kaasa S, Bjordal K, Aaronson N, et al and the EORTC Study Group on Quality of Life. The EORTC Core Quality of Life Questionnaire (QLQ-C30): validity and reliability when analysed with patients treated with palliative radiotherapy. Eur J Cancer 1995; 31A: 2260-63.
15. Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health related quality-of-life scores. J Clin Oncol 1998; 16: 9-144.
16. Spreen D, Strauss EA. A compendium of neuropsychological tests. Administration, norms, and commentary. Oxford University Press, 1998.
17. Klepstad P, Borchgrevink PC, Kaasa S. Effects on cancer fspatients' health related quality of life after start of morphine therapy. J Pain Symptom Manage 2000; 20: 19-26.
18. Sjøgren P, Thomsen AB, Olsen AK. Impaired neuropsychological performance in chronic non-malignant pain patients receiving long-term oral opioid treatment. J Pain Symptom Manage 2000; 19: 100-108.
19. Hart RP, Martelli MF, Zasler ND. Chronic pain and neuropsychological functioning. Neuropsychol Rev 2000; 10: 131-49.
20. Bruera E, Neumann CM. Role of methadone in the management of pain in cancer patients. Oncology 1999; 13: 1275-82.
21. Hagen NA, Wasylenko E. Methadone: outpatient titration and monitoring strategies in cancer patients. J Pain Symptom Manage 1999; 18: 369-75.
22. Mercadante S. Opioid rotation for cancer pain. Rationale and clinical aspects. Cancer 1999; 86: 1856-66.
23. Ettinger DS, Vitale PJ, Trump DL. Important clinical pharmacologic considerations in the use of methadone in cancer patients. Cancer Treat Rep 1979; 63: 457-59.
24. Hunt G, Bruera E. Respiratory depression in a patient receiving methadone for cancer pain. J Pain Symptom Manage 1995; 10: 401-404.
25. Anderson R, Saiers JH, Abram S, et al. Accuracy in equianalgesic dosing: Conversion dilemmas. J Pain Symptom Manage 2001; 32: 397-406.